Aligos Therapeutics (NASDAQ:ALGS) Sees Large Volume Increase

Aligos Therapeutics, Inc. (NASDAQ:ALGS) saw unusually-strong trading volume on Monday . Approximately 24,215 shares traded hands during trading, a decline of 16% from the previous session’s volume of 28,850 shares.The stock last traded at $8.86 and had previously closed at $8.04.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $75.00 price target on shares of Aligos Therapeutics in a research report on Friday, September 20th.

Aligos Therapeutics Price Performance

The stock has a 50-day simple moving average of $12.51 and a 200-day simple moving average of $15.51. The stock has a market cap of $673.31 million, a PE ratio of -6.73 and a beta of 2.18.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of ($4.00) by $4.75. The company had revenue of $1.06 million for the quarter. Aligos Therapeutics had a negative return on equity of 110.59% and a negative net margin of 1,100.48%. During the same quarter in the prior year, the firm earned ($10.75) EPS. As a group, equities research analysts anticipate that Aligos Therapeutics, Inc. will post -8.2 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Armistice Capital LLC acquired a new position in shares of Aligos Therapeutics during the fourth quarter worth about $4,538,000. Opaleye Management Inc. acquired a new position in shares of Aligos Therapeutics during the fourth quarter worth about $861,000. Acadian Asset Management LLC lifted its stake in shares of Aligos Therapeutics by 17.6% during the first quarter. Acadian Asset Management LLC now owns 657,995 shares of the company’s stock worth $644,000 after purchasing an additional 98,628 shares in the last quarter. Finally, Altitude Crest Partners Inc. acquired a new position in shares of Aligos Therapeutics during the fourth quarter worth about $1,889,000. Institutional investors and hedge funds own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).